Ipca Labs

Why is Ipca Laboratories Ltd falling/rising?

As of 14-Aug, Ipca Laboratories Ltd's stock price is declining, currently at 1,728.00, reflecting a 3.82% decrease after a trend reversal. Despite strong annual performance, recent movements indicate a short-term correction and underperformance relative to its sector.

As of 14-Aug, Ipca Laboratories Ltd's stock price is falling, currently at 1,728.00, which reflects a decrease of 68.6 points or 3.82%. This decline follows a trend reversal after three consecutive days of gains. The stock has underperformed its sector by 2.96% today and reached an intraday low of Rs 1720.45, marking a drop of 4.24%. <BR><BR>Despite the stock's strong performance over the year, generating a return of 26.33%, and positive financial indicators such as a 36.65% growth in net profit and a high operating cash flow, the recent price movement suggests a short-term correction. The stock is currently trading below its 5-day and 20-day moving averages, indicating a potential weakening in momentum. Additionally, while there has been a significant increase in delivery volume, up 299.44% against the 5-day average, this may not be enough to counteract the current downward pressure on the stock price. <BR><BR>Overall, the combination of recent performance trends, the stock's current positioning relative to moving averages, and the sector underperformance contribute to the observed decline in the stock price of Ipca Laboratories Ltd.

Should I buy, sell or hold Ipca Laboratories Ltd?

Which are the latest news on Ipca Labs?

Who are in the management team of Ipca Labs?

The management team of Ipca Labs includes Premchand Godha (Chairman), A K Jain (Managing Director & CFO), Pranay Godha (CEO), and several independent directors, along with Harish P Kamath as Company Secretary. They are responsible for the company's strategic direction and operations.

The management team of Ipca Labs includes the following key members:<BR><BR>1. **Premchand Godha** - Chairman / Executive Director<BR>2. **A K Jain** - Managing Director and Joint Managing Director & CFO<BR>3. **Pranay Godha** - Executive Director / Managing Director / CEO / Promoter<BR>4. **Prashant Godha** - Executive Director<BR>5. **Anand T Kusre** - Independent Director and Independent Non-Executive Director<BR>6. **Manisha Premnath** - Independent Director and Independent Non-Executive Director<BR>7. **Kamal Kishore Seth** - Independent Director and Independent Non-Executive Director<BR>8. **Narendra Mairpady** - Independent Director and Independent Non-Executive Director<BR>9. **Harish P Kamath** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Ipca Labs do?

Ipca Laboratories Ltd is a mid-cap pharmaceutical company, incorporated in 1949, specializing in pharmaceuticals and biotechnology. As of June 2026, it reported net sales of ₹2,788 Cr and a net profit of ₹402 Cr, with a market cap of ₹45,210 Cr.

Overview:<BR>Ipca Laboratories Ltd is a fully integrated pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Mid Cap.<BR><BR>History:<BR>Ipca Laboratories Limited was incorporated on 19 October 1949 under the name 'The Indian Pharmaceutical Combine Association Limited.' The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,788 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 402 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 45,210 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.34%<BR>- Debt Equity: -0.05<BR>- Return on Equity: 14.93%<BR>- Price to Book: 5.54<BR><BR>Contact Details:<BR>Address: 48 Kandivli Industrial Estate, Kandivli (West) Mumbai Maharashtra : 400067<BR>Tel: 91-22-66474444<BR>Email: ipca@ipca.co.in/investors@ipca.com<BR>Website: http://www.ipca.com

Who are the peers of the Ipca Labs?

Ipca Labs' peers include Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Sai Life, and Wockhardt. In terms of management risk, growth, and capital structure, they vary from excellent to below average, with Ipca Labs showing a 1-year return of 31.71%.

Peers: The peers of Ipca Labs are Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Sai Life, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Gland Pharma, Ipca Labs, and Emcure Pharma. Average management risk is noted at Sai Life and Wockhardt. In terms of Growth, Excellent growth is seen at Anthem Bioscienc and Emcure Pharma, while Average growth is found at Glenmark Pharma and Abbott India, and Below Average growth is observed at Alkem Lab, Gland Pharma, Ipca Labs, and Ajanta Pharma. For Capital Structure, Excellent capital structure is noted at Alkem Lab, Abbott India, Anthem Bioscienc, Gland Pharma, Ajanta Pharma, Ipca Labs, Glaxosmi. Pharma, and Sai Life, while Good capital structure is seen at Glenmark Pharma and Emcure Pharma, and Below Average capital structure is present at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sai Life at 60.82%, while Abbott India has the lowest at -16.28%. Ipca Labs has a 1-year return of 31.71%, which is significantly higher than Abbott India but lower than Sai Life. Additionally, no peers have a negative six-month return.

How big is Ipca Labs?

As of 14th August, Ipca Laboratories Ltd has a market capitalization of 43,855.31 Cr, with recent net sales of 10,125.58 Cr and net profit of 1,309.80 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Ipca Laboratories Ltd has a market capitalization of 43,855.31 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 10,125.58 Cr, while the sum of Net Profit for the same period is 1,309.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 8,063.81 Cr and Total Assets totaling 12,349.65 Cr.

Are Ipca Laboratories Ltd latest results good or bad?

Ipca Laboratories Ltd's latest results show strong year-on-year growth with a 340.98% increase in net profit, but sequentially, both profit and revenue declined, raising concerns about margin sustainability. Overall, the results are good year-on-year but troubling in terms of quarter-on-quarter performance.

Ipca Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year increase in consolidated net profit, soaring by 340.98% to ₹299.07 crore, and a 6.31% rise in revenue to ₹2,388.48 crore. This indicates a strong recovery from previous lows. However, the sequential performance raises concerns, as both net profit and revenue showed declines of 8.34% and 0.17% respectively compared to the previous quarter.<BR><BR>The operating margin also experienced a notable decline, dropping from 22.29% in the previous quarter to 20.26%. This margin compression, despite stable revenue, suggests rising cost pressures or unfavorable shifts in product mix, which could be a red flag for investors.<BR><BR>Overall, while the year-on-year growth figures are impressive, the sequential decline in profitability and margins indicates challenges that the company needs to address. Investors reacted negatively to these results, as reflected in the stock's decline following the announcement. Therefore, the latest results can be characterized as good in terms of year-on-year growth but concerning when looking at the quarter-on-quarter performance and margin sustainability.

Is Ipca Labs technically bullish or bearish?

As of December 1, 2025, the technical trend for Ipca Labs is mildly bearish, influenced by weak daily moving averages and monthly indicators, despite a bullish weekly MACD and mildly bullish Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating weakness and the monthly MACD showing a mildly bearish outlook. While the weekly MACD is bullish, the overall sentiment is tempered by the monthly indicators, including the KST and Dow Theory, which are also mildly bearish. The Bollinger Bands present a mildly bullish signal on both weekly and monthly time frames, but this is overshadowed by the bearish signals in moving averages and the lack of strong momentum in the RSI. Overall, the technical indicators suggest a cautious approach in the current market environment for Ipca Labs.

How has been the historical performance of Ipca Labs?

Ipca Labs has exhibited consistent growth in net sales and profitability, with net sales increasing from ₹3,773.18 Cr in Mar'19 to ₹8,939.59 Cr in Mar'25, and profit after tax rising from ₹444.03 Cr to ₹787.53 Cr during the same period. The company's financial performance reflects resilience, with improved operating profit and positive cash flow.

Answer:<BR>The historical performance of Ipca Labs shows a consistent growth trajectory in net sales and profitability over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Ipca Labs has demonstrated significant growth in net sales, rising from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. This upward trend is reflected in total operating income, which also increased from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. The total expenditure has risen correspondingly, from 3,081.30 Cr in Mar'19 to 7,213.45 Cr in Mar'25, yet the operating profit (PBDIT) has shown improvement, climbing from 749.56 Cr in Mar'19 to 1,818.94 Cr in Mar'25. Profit before tax has also increased from 548.27 Cr in Mar'19 to 1,131.14 Cr in Mar'25, while profit after tax reached 787.53 Cr in Mar'25, up from 444.03 Cr in Mar'19. The earnings per share (EPS) rose from 35.21 in Mar'19 to 29.08 in Mar'25, indicating a strong performance despite fluctuations in profitability. The company's total assets have expanded from 5,257.82 Cr in Mar'20 to 11,743.63 Cr in Mar'25, with total liabilities increasing from 5,257.82 Cr to 11,743.63 Cr during the same period. Cash flow from operating activities has improved, reaching 1,321.00 Cr in Mar'25 compared to 570.00 Cr in Mar'20, while net cash inflow turned positive at 168.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Ipca Labs has shown resilience and growth in its financial performance over the years.

Is Ipca Labs overvalued or undervalued?

As of September 2, 2025, Ipca Labs is fairly valued with a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, making it an attractive investment compared to its peers, Sun Pharma and Divi's Lab, which are considered expensive.

As of 2 September 2025, the valuation grade for Ipca Labs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, Ipca Labs stands out with a fair valuation while Sun Pharma is considered expensive with a PE of 32.69 and Divi's Lab is very expensive with a PE of 70.48. Notably, the company's return over the past year has been slightly better than the Sensex, which aligns with its fair valuation status. Overall, Ipca Labs presents a balanced investment opportunity within the pharmaceuticals and biotechnology sector.

Who are the top shareholders of the Ipca Labs?

The top shareholders of Ipca Labs include promoters holding 21.47%, mutual funds with a collective 29.63% (led by HDFC Mid-cap Opportunities Fund at 8.47%), foreign institutional investors at 10.76%, and individual investors at 6.81%.

The top shareholders of Ipca Labs include a mix of promoters, mutual funds, and foreign institutional investors. The majority shareholders are the promoters, with Kaygee Investments Private Limited holding the largest share at 21.47%. Mutual funds collectively hold 29.63% through 33 schemes, with HDFC Mutual Fund's HDFC Mid-cap Opportunities Fund being the highest public shareholder at 8.47%. Additionally, foreign institutional investors (FIIs) hold 10.76% of the company, while individual investors account for 6.81%.

When is the next results date for Ipca Labs?

No Upcoming Board Meetings

Has Ipca Labs declared dividend?

Ipca Laboratories Ltd has declared a 200% dividend, amounting to ₹2 per share, with an ex-date of November 27, 2024. The dividend yield is 0.29%, and the company has shown strong total returns over various periods, particularly in the long term.

Ipca Laboratories Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 2 per share<BR>- Ex-date: Nov-27-2024<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.73%, the dividend return was 0%, resulting in a total return of -9.73%.<BR><BR>Over the past year, the price return was 19.48%, the dividend return was 0.34%, leading to a total return of 19.82%.<BR><BR>In the 2-year period, the price return was 85.62%, the dividend return was 0.82%, culminating in a total return of 86.44%.<BR><BR>For the 3-year period, the price return was 60.69%, the dividend return was 1.12%, resulting in a total return of 61.81%.<BR><BR>In the last 4 years, the price return was 34.76%, the dividend return was 1.79%, leading to a total return of 36.55%.<BR><BR>Over the past 5 years, the price return was 84.96%, the dividend return was 3.14%, resulting in a total return of 88.1%.<BR><BR>Overall, Ipca Laboratories Ltd has declared a significant dividend while also demonstrating strong total returns over various periods, particularly in the longer term. The dividend yield remains modest, indicating a balanced approach between price appreciation and dividend distribution.